Kalorama Information: Tests That Personalize Results Show Sales Growth of up to 38%

ID: 1100986
recent pressrelease next pressrelease

(businesspress24) - NEW YORK, NY -- (Marketwire) -- 04/09/12 -- Diagnostic tests that can direct a therapy to a specific patient to boost outcomes and lower cost are experiencing faster sales growth, according to a recent report from Kalorama Information. The tracks sales of this category of tests, reporting growth falling anywhere between 7% and 38% per year, compared with the more modest two to six percent growth in IVD generally.

"Tests that can green light a therapeutic option have so far beat the traditional IVD tests, which offer broad disease indicators," said Bruce Carlson, publisher of Kalorama Information. "We think this is the dynamic area of the and this is why scores of companies are heavily involved in this sector."

Tests, including Fluorescent In Situ Hybridization (FISH) for cancer screening, CYP450 tests for psychiatric therapy, individual microbiologic assessments to treat infectious disease and tissue transplant typing, rose to $28.1 billion in 2011, according to the report. Kalorama's market estimate covers tests that can also provide therapy decision-making information that is tailored to the individual, which falls into four categories: Tests that identify a population in which the therapeutic product will achieve greater (or little) effectiveness, tests that identify a patient population that should not receive a particular therapeutic product, tests that identify the characteristics of a disease, and tests that are the basis for selecting a safe and efficacious therapeutic dose.

The primary growth drivers in the market for personalized medicine tests are the continued discovery of protein and genetic markers with proven clinical utility, the increased adoption of these diagnostic tests as markers for personalized medicine and increased acceptance. There are challenges, such as reimbursement issues, lack of standardization across test platforms, limited quality control products and programs, as well as the inability to fully interpret test data.

Kalorama Information's study, "" goes into detail about these challenges and their future impact on the market, lists specific personalized medicine tests that are poised to grow and profiles companies that are operating in these markets.

Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .

Please direct all media inquiries to:


Bruce Carlson



Keywords (optional):

personalized-medicine, diagnostic-test, ivd-market, fish, cyp450, healthcare-market-research,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: MARKETWIRE
print pressrelease  send to a friend  

Date: 04/09/2012 - 09:31
Language: English
News-ID 1100986
Character count: 0
Kontakt-Informationen:
Firma: Kalorama Information
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: NEW YORK, NY
Telefon:

Comments:



Number of hits: 96

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 62


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.